Effect of Supplementation With Creatine on the Recovery of Ischemic Stroke

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Stroke, Ischemic

In brief

Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion. Post-stroke treatment focuses on secondary prevention and rehabilitation, but few treatments address functional recovery. Creatine, a supplement known for improving physical performance, may aid in the recovery of stroke patients, reducing sarcopenia and improving strength among other effects. This pilot study will investigate the effectiveness of creatine supplementation in enhancing physical and functional recovery in ischemic stroke patients. The study will involve a randomized, double-blind clinical trial comparing creatine monohydrate to a placebo.

Key facts

Study ID

NCT06576466

Run by

Fundació d'investigació Sanitària de les Illes Balears

People needed

92

Starts

2024-09-27

Expected to finish

2027-07-01

Last updated by the study team

2025-07-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 80 years
• Recent diagnosis of ischemic stroke (from 24 hours to 5 days) .
• Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation.
• Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study.

You may not qualify if…

• Moderate-severe disability prior to stroke, defined by an mRS>2.
• Unstable or severe clinical situation that prevents active rehabilitation.
• Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is permitted.
• Moderate or severe dysphagia that makes therapeutic adherence difficult.
• Use of creatine supplements in the last 3 months, or use of anabolic products in the last 3 months.
• Severe kidney disease (GFR <30ml/min/1.73 m2).
• Musculoskeletal pathology that prevents assessment of muscle strength. For example: fractures, severe osteoarthritis, ligament tears or tendinopathies.
• History of allergic reactions to creatine.
• Pregnancy or breastfeeding.
• Simultaneous participation in another clinical trial.

Where it is running

• IdISBa — Palma de Mallorca, Balearic Islands, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.